Literature DB >> 6228739

Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome.

S L Hoffman, W F Piessens, S Ratiwayanto, P R Hussein, L Kurniawan, P W Piessens, J R Campbell, H A Marwoto.   

Abstract

To study the pathogenesis of tropical splenomegaly syndrome, we compared immunologic findings in patients from Flores, Indonesia, with those obtained in local residents without splenomegaly and in controls. Villagers with tropical splenomegaly syndrome had markedly elevated levels of total IgM, higher titers of IgM antibodies to Plasmodium vivax, and reduced levels of circulating T lymphocytes. The latter were caused by a decrease in the total number of T cells with the suppressor/cytotoxic phenotype (T8+). Levels of B lymphocytes were similar in all groups. All immunologic abnormalities reverted toward normal in patients treated weekly for 9 to 26 months with chloroquine phosphate. These findings suggest that overproduction of immunoglobulins in patients with tropical splenomegaly syndrome is caused by an imbalance in the normal ratio of helper: suppressor T cells that regulate B-lymphocyte function, and that this imbalance is due to a decrease in suppressor T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6228739     DOI: 10.1056/NEJM198402093100601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  11 in total

1.  Hyperreactive Malarial Splenomegaly Syndrome--Can the Diagnostic Criteria Be Improved?

Authors:  Alastair McGregor; Tom Doherty; Patricia Lowe; Peter Chiodini; William Newsholme
Journal:  Am J Trop Med Hyg       Date:  2015-07-20       Impact factor: 2.345

2.  Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab.

Authors:  Barathy Rani Ramasamy; Patrick Charles; Douglas Johnson; Albert Frauman
Journal:  BMJ Case Rep       Date:  2017-09-01

3.  Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.

Authors:  J E Craft; D K Fischer; G T Shimamoto; A C Steere
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population.

Authors:  H M Dosch; C J Ledgley; D White; P Lam; G B Mills
Journal:  J Clin Immunol       Date:  1985-09       Impact factor: 8.317

5.  T4 lymphopenia in patients with active pulmonary tuberculosis.

Authors:  J S Beck; R C Potts; T Kardjito; J M Grange
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

6.  Antibody-mediated killing of suppressor T lymphocytes as a possible cause of macroglobulinemia in the tropical splenomegaly syndrome.

Authors:  W F Piessens; S L Hoffman; A A Wadee; P W Piessens; S Ratiwayanto; L Kurniawan; J R Campbell; H A Marwoto; L L Laughlin
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

7.  CD8+ T cells inhibit Plasmodium falciparum-induced lymphoproliferation and gamma interferon production in cell preparations from some malaria-immune individuals.

Authors:  E M Riley; O Jobe; H C Whittle
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

8.  Hyper-reactive malarial splenomegaly (HMS) in a patient with β thalassaemia syndrome.

Authors:  Yaw Ampem Amoako; George Bedu-Addo
Journal:  Pan Afr Med J       Date:  2014-11-21

Review 9.  The hyper-reactive malarial splenomegaly: a systematic review of the literature.

Authors:  Stefania Leoni; Dora Buonfrate; Andrea Angheben; Federico Gobbi; Zeno Bisoffi
Journal:  Malar J       Date:  2015-04-29       Impact factor: 2.979

10.  Early hyperreactive malarial splenomegaly and risk factors for evolution into the full-blown syndrome: a single-centre, retrospective, longitudinal study.

Authors:  Zeno Bisoffi; Stefania Leoni; Dora Buonfrate; Claudia Lodesani; Franklin Esoka Eseme; Geraldo Badona Monteiro; Stefania Marocco; Massimo Guerriero
Journal:  Malar J       Date:  2015-12-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.